Velioğlu Yusuf, Yüksel Ahmet, Sınmaz Emrah
Department of Cardiovascular Surgery, Abant İzzet Baysal University Faculty of Medicine, Bolu, Turkey.
Department of Thoracic Surgery, Bursa Ali Osman Sönmez Oncology Hospital.
Turk Gogus Kalp Damar Cerrahisi Derg. 2019 Oct 23;27(4):499-507. doi: 10.5606/tgkdc.dergisi.2019.17972. eCollection 2019 Oct.
The aim of this study was to present clinical characteristics, peri-procedural outcomes, early and late complications, and management strategies in patients undergoing totally implantable venous access port insertion through percutaneous subclavian vein.
A total of 2,084 port devices were inserted to 2,000 cancer patients (1,066 males, 934 females; mean age 58.4±12.7 years; range, 18 to 88 years) through subclavian vein using percutaneous landmark method between March 2012 and June 2018. Medical data including demographic features, primary diagnosis, technical success, procedural time, duration of device use, reasons for the device removal, and early and late complications were retrospectively analyzed.
The most common type of cancer was colon cancer in males and breast cancer in females. Technical success rate of the procedure was 98.5%. Right subclavian vein was accessed in the majority of patients (92.4%). Early complications including inadvertent arterial puncture, catheter malposition, superficial hematoma, and pneumothorax occurred in 143 patients (6.9%), while late complications including infection, catheter occlusion, venous thrombosis, wound problems, catheter migration and embolization and pinch-off syndrome was developed in 118 patients (5.7%). Inadvertent arterial puncture in 63 patients (3%) was the most common early complication, while infection in 44 patients (2.1%) was the most common late complication. A total of 192 devices were removed due to the completion of chemotherapy or development of complications.
Our study confirmed the safety and tolerability of totally implantable venous access port insertion through percutaneous subclavian vein with high technical success and low complication rates.
本研究旨在呈现经皮锁骨下静脉植入全植入式静脉通路端口患者的临床特征、围手术期结果、早期和晚期并发症以及管理策略。
2012年3月至2018年6月期间,采用经皮体表定位法,通过锁骨下静脉为2000例癌症患者(1066例男性,934例女性;平均年龄58.4±12.7岁;范围18至88岁)植入了2084个端口装置。对包括人口统计学特征、初步诊断、技术成功率、手术时间、装置使用时长、装置移除原因以及早期和晚期并发症在内的医疗数据进行回顾性分析。
男性中最常见的癌症类型是结肠癌,女性中是乳腺癌。该手术的技术成功率为98.5%。大多数患者(92.4%)选择了右锁骨下静脉。143例患者(6.9%)出现了早期并发症,包括意外动脉穿刺、导管位置不当、浅表血肿和气胸;118例患者(5.7%)出现了晚期并发症,包括感染、导管堵塞、静脉血栓形成、伤口问题、导管移位和栓塞以及夹闭综合征。63例患者(3%)发生的意外动脉穿刺是最常见的早期并发症,44例患者(2.1%)发生的感染是最常见的晚期并发症。共有192个装置因化疗结束或出现并发症而被移除。
我们的研究证实了经皮锁骨下静脉植入全植入式静脉通路端口的安全性和耐受性,技术成功率高且并发症发生率低。